Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
February 13 2024 - 8:00AM
Esperion (NASDAQ: ESPR), today announced it will report fourth
quarter and full year 2023 financial results before the market
opens on Tuesday, February 27, 2024.
Following the release, management will host a
webcast at 8:00 a.m. ET to discuss these financial results and
provide business updates. Please click here to pre-register to
participate in the conference call and obtain your dial in number
and PIN.
Already registered? Access with your PIN here.
A live audio webcast can be accessed on the investor and media
section of the Esperion website. Access to the webcast replay will
be available approximately two hours after completion of the call
and will be archived on the Company's website for approximately 90
days.
Esperion TherapeuticsAt Esperion, we discover,
develop, and commercialize innovative medicines to help improve
outcomes for patients with or at risk for cardiovascular and
cardiometabolic diseases. The status quo is not meeting the health
needs of millions of people with high cholesterol – that is why our
team of passionate industry leaders is breaking through the
barriers that prevent patients from reaching their goals. Providers
are moving toward reducing LDL-cholesterol levels as low as
possible, as soon as possible; we provide the next steps to help
get patients there. Because when it comes to high cholesterol,
getting to goal is not optional. It is our life’s work. For more
information, visit esperion.com and esperionscience.com and follow
us on Twitter at twitter.com/EsperionInc.
Esperion Contact Information: Investors: Alexis
Callahaninvestorrelations@esperion.com (406) 539-1762
Media: Tiffany Aldrich corporateteam@esperion.com (616)
443-8438
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024